EFTA00292520Set 9
2014-07-1720p1,258w
clinical development costs
• Clinical grant application — (Q2, 2017) — up to $5M
/ Covers 70% of Phaselb Clinical trial costs
Therapeutic focus:
• Rebuild new blood and immune system by transplanting
https://www.justice.gov/epstein/files/DataSet%209/EFTA00292520.pdf